Pfizer to acquire obesity drug developer Metsera for $4.9 billion
Tweet Send to a Friend
Pfizer Inc. (NYSE: PFE) announced it will acquire Metsera Inc. (NASDAQ: MTSR), a clinical-stage biopharmaceutical company focused on obesity and ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


